Zynerba Redirects Resources After ZYN001 Study Fails To Meet Top-Line Results

Zynerba Pharmaceuticals Inc ZYNE shares plunged premarket Thursday after the company ended a clinical study for a tetrahydrocannabinol patch. 

What Happened

The Phase 1 study for the ZYN001 patch did not achieve targeted top-line results, Zynerba said in a statement. 

Why It’s Important

Although the pro-drug of tetrahydrocannabinol was “very well tolerated” by the skin and no adverse events were reported, Zynerba is terminating the study.

It will instead focus its time and resources on ZYN002 for Fragile X syndrome, developmental and epileptic encephalopathy and adult refractory epilepsy. The change is expected to extend Zynerba’s cash runway into the back half of 2019.

What’s Next

ZYN002 will begin a pivotal study of ZYN002 in Fragile X in “mid-year 2018” and continue Phase 2 trials for the other two indications.

Shares were trading down nearly 22 percent at the time of publication premarket Thursday. 

Related Links:

GW Pharma's Epidiolex Becomes First Cannabis-Based FDA-Approved Drug

Why Cannabis Investors Are Eyeing South America